onabotulinumtoxinA · Botox

Biologic (subtype unspecified)

Approvedregulatory verdict

Evidence outlook

Approved: Migraine

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Also approved (10)
US
  • Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck painFDA label
  • Adult Bladder Dysfunction Overactive Bladder BOTOX for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication. Detrusor Overactivity associated with a Neurologic Condition BOTOX is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g., SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.
    FDA label
  • Primary Axillary Hyperhidrosis BOTOX is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.FDA label
  • Treatment of strabismus in patients 12 years of age and olderFDA label
  • Blepharospasm associated with dystonia in patients 12 years of age and olderFDA label
  • Neurogenic detrusor overactivity in pediatric patients 5 years of age and older with inadequate response to or intolerance of anticholinergicsFDA label
  • Botox Cosmetic: temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adultsFDA label
  • Botox Cosmetic: temporary improvement in the appearance of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adultsFDA label
  • Botox Cosmetic: temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adultsFDA label
  • Botox Cosmetic: temporary improvement in the appearance of moderate to severe platysma bands associated with platysma muscle activity in adultsFDA label
Product first approved 1991Outside this platform's coverage
Featured evidence outside this drug's tracked markets:NCT06794866 · Forehead Lines · Phase 3 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (77)
Migraine
NCT07040813 · Oslo University Hospital
2025-06-06 – 2029-04-30 · Migraine, Chronic Migraine Headache
What this study did
NCT05028569 · AbbVie
2021-11-05 – 2024-11-06 · Episodic Migraine
What this study did
NCT03193359 · Allergan
2018-01-15 – 2021-09-09 · Migraine Disorders
What this study did
NCT03193346 · Allergan
2017-07-03 – 2021-03-25 · Migraine Disorders
What this study did
Other / comorbidity
NCT05698979 · University Hospital, Toulouse
2027-01-01 – 2028-02 · Buerger Disease, Raynaud Syndrome
What this study did
NCT06839118 · Danish Headache Center
2025-01-10 – 2026-08-01 · Posttraumatic Headache
What this study did
NCT06387394 · AbbVie
2024-04-22 – 2025-11-25 · Masseter Muscle Prominence
What this study did
NCT06068855 · AbbVie
2023-10-17 – 2025-11-20 · Masseter Muscle Prominence
What this study did
NCT06399718 · AbbVie
2024-04-30 – 2025-11-10 · Masseter Muscle Prominence
What this study did
NCT03616067 · Hospices Civils de Lyon
2022-04-27 – 2025-09-22 · Cerebral Palsy
What this study did
NCT02580838 · National Cheng-Kung University Hospital
2015-08 – 2025-09 · Stroke
What this study did
NCT06137287 · AbbVie
2023-11-22 – 2025-07-31 · Masseter Muscle Prominence
What this study did
NCT05573581 · Cairo University
2023-01 – 2025-01 · Orthognathic Relapse
What this study did
NCT05415865 · Herlev and Gentofte Hospital
2022-09-12 – 2024-05-01 · Urge Incontinence, Overactive Bladder, Anesthesia, Local, Pain, Procedural, Urinary Tract Infections, Hematuria
What this study did
NCT04171531 · NICHD Pelvic Floor Disorders Network
2020-06-08 – 2024-02-12 · Urinary Incontinence, Stress, Urinary Incontinence, Urge
What this study did
NCT05134649 · AbbVie
2021-11-16 – 2023-08-18 · Platysma Prominence
What this study did
NCT03459092 · Insel Gruppe AG, University Hospital Bern
2018-08-16 – 2023-07-31 · Acquired Esotropia
What this study did
NCT04994535 · AbbVie
2021-08-10 – 2023-06-14 · Platysma Prominence
What this study did
NCT04073303 · AbbVie
2019-08-29 – 2022-11-10 · Masseter Muscle Prominence
What this study did
NCT03555916 · Assistance Publique - Hôpitaux de Paris
2019-04-04 – 2022-11-08 · Trigeminal Neuropathy, Traumatic
What this study did
NCT02555982 · University Hospital, Clermont-Ferrand
2016-06-27 – 2022-09-01 · Essential Head Tremor
What this study did
NCT02097121 · Allergan
2014-05-23 – 2022-02-10 · Urinary Incontinence, Urinary Bladder, Overactive
What this study did
NCT03433859 · Direction Centrale du Service de Santé des Armées
2016-03 – 2021-03-03 · Hyperhidrosis, Residual Limbs
What this study did
NCT03717961 · Assistance Publique - Hôpitaux de Paris
2018-10-15 – 2020-07-31 · Raynaud Phenomenon Secondary to Systemic Sclerosis
What this study did
NCT01852058 · Allergan
2014-01-11 – 2019-10-03 · Urinary Incontinence
What this study did
NCT03408236 · Hugel
2018-01-17 – 2019-06-07 · Crow's Feet Lines
What this study did
NCT01852045 · Allergan
2013-07-02 – 2018-10-11 · Urinary Incontinence
What this study did
NCT01603615 · Allergan
2012-10-30 – 2018-09-03 · Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
What this study did
NCT01603641 · Allergan
2012-11-05 – 2018-08-25 · Pediatrics, Muscle Spasticity, Cerebral Palsy
What this study did
NCT01050114 · Christopher Patrick Smith
2013-08 – 2018-07 · Overactive Bladder
What this study did
NCT01591746 · Mayo Clinic
2012-08 – 2017-07-18 · Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms
What this study did
NCT01603602 · Allergan
2012-07-12 – 2017-07-06 · Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
What this study did
NCT01603628 · Allergan
2012-09-11 – 2017-06-28 · Pediatrics, Muscle Spasticity, Cerebral Palsy
What this study did
NCT02145689 · Allergan
2014-08 – 2017-05 · Muscle Spasticity, Stroke
What this study did
NCT02078895 · University of California, Irvine
2014-02 – 2017-02 · Lower Urinary Tract Discomfort, Stent Pain
What this study did
NCT02767635 · National Cheng-Kung University Hospital
2012-01 – 2016-12 · Tennis Elbow
What this study did
NCT02160535 · University of Washington
2014-05 – 2016-08 · Chronic Post Traumatic Headache
What this study did
NCT01502956 · NICHD Pelvic Floor Disorders Network
2012-02 – 2016-07 · Urinary Incontinence, Urge
What this study did
NCT02261467 · Allergan
2014-10-21 – 2016-04-26 · Forehead Rhytides, Glabellar Rhytides
What this study did
NCT02261493 · Allergan
2014-10-27 – 2016-04-20 · Facial Rhytides, Glabellar Rhytides
What this study did
NCT02145676 · Allergan
2014-05 – 2015-12 · Muscle Spasticity, Stroke
What this study did
NCT01829763 · Assistance Publique Hopitaux De Marseille
2013-04 – 2015-11 · Hemiplegic Patients Post-AVC
What this study did
NCT01422161 · NYU Langone Health
2010-04 – 2015-10 · Stroke With Hemiparesis
What this study did
NCT02165111 · Johns Hopkins University
2015-01 – 2015-09 · Scleroderma, Raynaud's Syndrome
What this study did
Phase 2/3 (13)
Migraine
NCT00660192 · Yale University
2008-01 – 2015-07 · Refractory Migraine
What this study did
Other / comorbidity
NCT06902805 · Assistance Publique - Hôpitaux de Paris
2025-12-03 – 2028-11 · Base-of-thumb Osteoarthritis, Osteoarthritis
What this study did
NCT06721520 · The Cleveland Clinic
2024-12-03 – 2028-05-31 · Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
What this study did
NCT04695600 · All India Institute of Medical Sciences
2023-08-11 – 2027-09-01 · Transfer Dysphagia, Oropharyngeal Dysphagia, Cricopharyngeus Muscle Dysfunction
What this study did
NCT05878951 · Northwestern University
2023-07-13 – 2026-12 · Urinary Incontinence, Overactive Bladder Syndrome, Overactive Bladder, Urologic Diseases
What this study did
NCT06755099 · Assiut University
2025-01-01 – 2026-11-30 · Female Sexual Dysfunction
What this study did
NCT06851598 · Abdallah Mohamed Abdallah Mohamed Elgendy
2024-07-01 – 2025-03-01 · Premature Ejaculation
What this study did
NCT04172558 · Benha University
2019-03-10 – 2022-11-01 · Erectile Dysfunction
What this study did
NCT01780636 · Karen Noblett
2013-01 – 2014-07 · Non-relaxing Puborectalis Syndrome
What this study did
NCT01350375 · The Research Center of Southern California
2009-09 – 2013-01 · Forward Head Posture With Associated Episodic Headache Disorder
What this study did
NCT02428881 · University College, London
2009-11 – 2012-07 · Urinary Retention, Fowler's Syndrome
What this study did
NCT01566292 · Catholic University of the Sacred Heart
2009-09 – 2010-09 · Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE)
What this study did
NCT00479596 · Urological Sciences Research Foundation
2007-01 – 2007-05 · Overactive Bladder
What this study did
Phase 2 (73)
Migraine
NCT03543254 · Norwegian University of Science and Technology
2018-05-01 – 2021-01-01 · Migraine Disorders, Chronic Disease
What this study did
NCT04578782 · IRCCS National Neurological Institute "C. Mondino" Foundation
2018-03-13 – 2020-05-31 · Migraine
What this study did
NCT03055767 · University of California, Irvine
2017-03-01 – 2020-04-20 · Migraine Disorders, Headache, Migraine, Pediatrics
What this study did
Other / comorbidity
NCT07880860 · Children's National Research Institute
2026-02-19 – 2032-02 · Cleft Lip, Cleft Lip Scar
What this study did
NCT07878780 · Weill Medical College of Cornell University
2026-12-01 – 2031-08 · Masticatory Myofascial Pain Syndrome
What this study did
NCT06530524 · Sir Mortimer B. Davis - Jewish General Hospital
2024-10-01 – 2027-12-01 · Head Neck Cancer, Xerostomia Following Radiotherapy
What this study did
NCT07923448 · Project Skin MD
2026-12 – 2027-03 · Wrinkles and Rhytides
What this study did
NCT06807164 · Centre Oscar Lambret
2025-06-10 – 2026-09-22 · Post-Mastectomy Neuropathic Pain Syndrome
What this study did
NCT07834164 · Clinica Universidad de Navarra, Universidad de Navarra
2024-11-25 – 2026-07-02 · Erectile Dysfunction
What this study did
NCT04794504 · Kingsway Oral & Maxillofacial Surgery
2021-04-19 – 2026-04-19 · Pain, Postoperative
What this study did
NCT05123053 · Augusta University
2021-10-28 – 2025-09-23 · Vocal Weakness(Post-BOTOX Injection)
What this study did
NCT03848143 · Isabel Moreno Hay
2019-09-11 – 2025-06-30 · Neuropathic Pain
What this study did
NCT05216250 · AbbVie
2022-04-12 – 2025-02-03 · Upper Limb Essential Tremor (UL ET)
What this study did
NCT05141006 · AbbVie
2022-03-29 – 2024-12-06 · Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
What this study did
NCT05275647 · Buddhist Tzu Chi General Hospital
2021-05-18 – 2024-09 · Interstitial Cystitis
What this study did
NCT06003049 · RMW Testing
2023-10-01 – 2024-07-10 · COPD
What this study did
NCT04502264 · Cheng-Hsin General Hospital
2020-01-09 – 2024-02-09 · Chronic Stroke, Spasticity as Sequela of Stroke, Robotic Rehabilitation
What this study did
NCT05012566 · Azienda Ospedaliera Universitaria Integrata Verona
2021-07-14 – 2023-07-14 · Hemifacial Paralysis
What this study did
NCT04401176 · Walter Reed National Military Medical Center
2020-09-15 – 2023-06-01 · Interstitial Cystitis, Bladder Pain Syndrome
What this study did
NCT04991688 · University Hospital, Bordeaux
2021-09-01 – 2023-03-03 · Low Anterior Resection Syndrome (LARS>20), Refractory Medical Treatment After Rectal Resection
What this study did
NCT05673655 · Fayoum University
2022-12-25 – 2023-02-25 · Myofacial Pain
What this study did
NCT05100199 · Allergan
2021-10-06 – 2022-12-02 · Glabellar Lines
What this study did
NCT02035397 · Norwegian University of Science and Technology
2014-02 – 2022-12 · Obesity, Morbid
What this study did
NCT05152576 · Allergan
2021-11-29 – 2022-09-06 · Forehead Lines
What this study did
NCT05013424 · Allergan
2021-09-01 – 2022-07-07 · Glabellar Lines
What this study did
NCT03462290 · Norwegian University of Science and Technology
2018-05-01 – 2021-11-23 · Facial Pain
What this study did
NCT04755595 · State University of New York - Downstate Medical Center
2021-03-09 – 2021-05-19 · Dermatological Non-Disease
What this study did
NCT04763265 · Croma-Pharma GmbH
2020-06-24 – 2021-02-01 · Frown Lines
What this study did
NCT02662530 · Western University, Canada
2012-01 – 2021-01 · Cervical Dystonia
What this study did
NCT03320850 · Allergan
2017-10-04 – 2020-07-21 · Urinary Incontinence, Overactive Bladder With Urinary Incontinence
What this study did
NCT03861936 · Allergan
2019-05-16 – 2020-07-02 · Masseter Muscle Prominence
What this study did
NCT03915067 · Allergan
2019-04-23 – 2020-04-16 · Platysma Prominence
What this study did
NCT03827122 · Riyadh Colleges of Dentistry and Pharmacy
2018-11-13 – 2019-11-13 · Nocturnal Bruxism
What this study did
NCT01930604 · Carl Swartling
2013-09 – 2019-10 · Hyperhidrosis
What this study did
NCT03301272 · University of North Carolina, Chapel Hill
2018-03-22 – 2019-08-21 · Parkinson Disease
What this study did
NCT02160288 · Massachusetts General Hospital
2016-02 – 2019-06-11 · Obstructed Defecation Syndrome (ODS)
What this study did
NCT03631368 · Roy G. Geronemus, M.D.
2018-10-01 – 2019-05-31 · Hypertrophic Scar
What this study did
NCT02623829 · Icahn School of Medicine at Mount Sinai
2015-12-01 – 2019-03-01 · Post-operative Excessive Scarring
What this study did
NCT00812838 · Mohit Khera
2009-08-07 – 2019-01-15 · Peyronie's Disease
What this study did
NCT02784262 · Norwegian University of Science and Technology
2016-10 – 2018-12 · Chronic Disease, Nasal Polyposis, Rhinitis
What this study did
NCT02249234 · Mount Sinai Hospital, Canada
2014-08 – 2018-10 · Scrotal Pain
What this study did
NCT03097835 · Steve Yoelin M.D. Medical Associates, Inc.
2018-02-12 – 2018-07-26 · Skin Quality
What this study did
NCT02010775 · Allergan
2014-01-20 – 2017-11-29 · Masseter Muscle Hypertrophy
What this study did
NCT01374191 · Southern Illinois University
2015-01 – 2017-09 · Neuroma
What this study did
NCT01917006 · Allergan
2013-08-07 – 2017-08-15 · Premature Ejaculation
What this study did
NCT03076762 · Buddhist Tzu Chi General Hospital
2015-03 – 2017-08 · Bladder Pain Syndrome
What this study did
NCT02247557 · Buddhist Tzu Chi General Hospital
2014-09 – 2017-02 · Interstitial Cystitis
What this study did
NCT02116361 · Allergan
2014-04-22 – 2016-12-22 · Depressive Disorder, Major
What this study did
NCT02058836 · Wake Forest University Health Sciences
2014-11 – 2016-10-18 · Chronic Testicular Pain
What this study did
Phase 1/2 (19)
Migraine
NCT02074163 · ASIS Corporation
2016-01 – 2017-06 · Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
What this study did
NCT02259075 · Norwegian University of Science and Technology
2015-02 – 2016-03 · Migraine Disorders
What this study did
Other / comorbidity
NCT07796490 · The Methodist Hospital Research Institute
2026-11-01 – 2029-11-01 · Prostate Cancer
What this study did
NCT05512039 · Dartmouth-Hitchcock Medical Center
2023-05-12 – 2027-01-01 · Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
What this study did
NCT06543979 · Ain Shams University
2024-09-07 – 2025-10-01 · Chronic Constipation
What this study did
NCT05892770 · University of Florida
2023-08-01 – 2025-03-01 · Spasmodic Dysphonia
What this study did
NCT04585620 · Allan Vestergaard Danielsen, MD
2022-09-01 – 2024-01-31 · Chronic Pain, Post-thoracotomy Pain Syndrome, Pain, Neuropathic, Pain, Postoperative
What this study did
NCT06044883 · Cairo University
2023-06-01 – 2024-01-01 · Erectile Dysfunction
What this study did
NCT03991299 · Vanderbilt University Medical Center
2021-04-29 – 2022-02-11 · Obese, Diabetes Mellitus, Type 2
What this study did
NCT03922139 · University of Wisconsin, Madison
2019-10-08 – 2021-12-15 · Compartment Syndrome of Leg
What this study did
NCT02074150 · li nguyen
2016-01 – 2017-06 · Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
What this study did
NCT02074293 · li nguyen
2016-01 – 2017-06 · Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
What this study did
NCT02639052 · Temple University
2016-02 – 2017-01 · Pruritus
What this study did
NCT01997983 · UroGen Pharma Ltd.
2013-11 – 2015-08 · Interstitial Cystitis, IC
What this study did
NCT02019017 · Norwegian University of Science and Technology
2013-10 – 2014-08 · Cluster Headache
What this study did
NCT01088230 · New York Presbyterian Hospital
2009-06 – 2010-11 · Stroke
What this study did
NCT00732680 · Mayo Clinic
2008-12 – 2009-11 · Empty Nose Syndrome, Atrophic Rhinitis
What this study did
NCT00178945 · Vanderbilt University
2004-03 – 2006-03 · Refractory Cervicothoracic Myofascial Pain Syndrome (CMPS), Cervical Dystonia
What this study did
Phase 1 (42)
Migraine
NCT04580238 · University of Alberta
2023-12 – 2025-06 · Stroke (CVA) or TIA, Headache, Migraine, Botulinum Toxins, Type A, Cerebral Venous Sinus Thrombosis, Carotid Dissection Artery, Vertebral Dissection Artery, Hemorrhagic Stroke, Reversible Cerebral Vasoconstriction Syndrome
What this study did
Other / comorbidity
NCT06785844 · Shaare Zedek Medical Center
2025-07-01 – 2030-09 · Fecal Incontinence
What this study did
NCT06793683 · University of Washington
2024-07-27 – 2028-09-30 · Spinal Cord Injuries
What this study did
NCT07648290 · The Cleveland Clinic
2026-07-31 – 2028-03-31 · Overactive Bladder
What this study did
NCT02019004 · Northwestern University
2013-11 – 2027-12 · Wrinkles
What this study did
NCT04984317 · Northwell Health
2022-02-14 – 2027-08 · Stress Urinary Incontinence
What this study did
NCT06796985 · University of Miami
2025-02-24 – 2027-03-22 · Pelvic Floor Disorders
What this study did
NCT07756580 · AbbVie
2026-08-10 – 2027-03 · Glabellar Lines
What this study did
NCT05766683 · Henry Ford Health System
2023-03-14 – 2026-12 · Glabellar Frown Lines
What this study did
NCT07645456 · Benha University
2025-10-01 – 2026-04-20 · Benign Prostatic Hyperplasia
What this study did
NCT06778421 · Center for Advanced Facial Plastic Surgery
2025-03-19 – 2026-01-10 · Stress (Psychology), Stress, Healthy Adult Female Participants, Stress, Psychologic, Stress, Psychological Cumulative, Stress, Physiological, Stress Response, Stress Levels, Stress Perception
What this study did
NCT04630873 · University of Ioannina
2020-11-20 – 2025-08-01 · Post Stroke Spastic Hemiplegia
What this study did
NCT04715048 · University of Southern California
2021-01-01 – 2025-06 · Glabellar Frown Lines
What this study did
NCT05769478 · Wake Forest University Health Sciences
2023-09-15 – 2024-10-29 · Botulism, Iatrogenic Botulism
What this study did
NCT07792798 · Sana'a University
2022-09-13 – 2024-10-17 · Oromandibular Dystonia, Electromyography
What this study did
NCT06013644 · Cairo University
2023-06-03 – 2024-02-01 · Myofascial Trigger Point Pain, Myofascial Pain Syndrome
What this study did
NCT04030767 · Cairo University
2019-09-20 – 2022-09-20 · Gingival Overgrowth
What this study did
NCT05083286 · Clinical Testing of Beverly Hills
2021-10-20 – 2022-08-01 · Glabellar Frown Lines
What this study did
NCT03236012 · University of Utah
2019-01-08 – 2022-02-14 · Hyperhidrosis
What this study did
NCT04631588 · Allergan
2020-11-16 – 2021-11-03 · Facial Fine Lines
What this study did
NCT04523506 · University of Texas Southwestern Medical Center
2020-05-08 – 2021-04-22 · Scleroderma
What this study did
NCT04439825 · DeNova Research
2020-07-20 – 2020-12-01 · Mood
What this study did
NCT03616262 · VA Connecticut Healthcare System
2016-07 – 2019-12 · Complex Regional Pain Syndrome
What this study did
NCT03069911 · Johns Hopkins University
2018-11-01 – 2019-06-01 · Parkinson Disease, Depression
What this study did
NCT03647982 · Medy-Tox
2018-03-20 – 2018-11-20 · Anhidrotic Area, Hyperhidrosis
What this study did
NCT03547141 · Medy-Tox
2018-04-16 – 2018-11-01 · Healthy
What this study did
NCT03317717 · Medy-Tox
2017-10-12 – 2018-01-30 · Healthy
What this study did
NCT03103594 · University of Pennsylvania
2015-08 – 2017-04 · Bladder Pain Syndrome
What this study did
NCT02524236 · Beni-Suef University
2015-08 – 2016-11 · Benign Prostatic Hyperplasia
What this study did
NCT02173405 · University Hospitals Cleveland Medical Center
2014-08-01 – 2016-09-01 · Myofascial Pain Syndromes, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
What this study did
NCT02202070 · Washington University School of Medicine
2015-01 – 2015-12 · Temporomandibular Joint Disorders, Bruxism, Temporomandibular Joint Dysfunction Syndrome, Myofascial Pain Dysfunction Syndrome, Temporomandibular Joint
What this study did
NCT01832194 · Mount Sinai Hospital, Canada
2013-03 – 2014-04 · Scrotal Pain
What this study did
NCT01520441 · The University of Texas Health Science Center, Houston
2011-03 – 2014-03 · Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
What this study did
NCT01352546 · Plastic Surgery Professional Association
2010-08 – 2012-12 · Vaginismus
What this study did
NCT00565201 · Emory University
2007-10 – 2011-12 · Stroke
What this study did
NCT00529386 · Queen's University
2006-01 – 2009-12 · Prostatitis, Chronic Pain Syndrome
What this study did
NCT00280280 · Vanderbilt University
2006-02 – 2009-02 · Spasticity
What this study did
NCT00279903 · Mayo Clinic
2005-11 – 2008-08 · Osteoarthritis, Knee
What this study did
NCT00175604 · University of British Columbia
2004-08 – 2008-02 · Torticollis
What this study did
Phase 4 (116)
Migraine
NCT07780136 · Assiut University
2026-10 – 2026-12 · Chronic Migraine Headache
What this study did
NCT05724771 · Chicago Headache Center & Research Institute
2023-01-26 – 2025-05 · Chronic Migraine, Headache
What this study did
NCT03381261 · Massachusetts General Hospital
2017-12-01 – 2023-12-01 · Migraine
What this study did
NCT05284019 · H. Lundbeck A/S
2022-03-04 – 2023-04-14 · Migraine
What this study did
NCT03698409 · State University of New York - Upstate Medical University
2019-01-01 – 2019-08-01 · Chronic Migraine, Headache
What this study did
NCT03606356 · Corfu Headache Clinic
2015-04-01 – 2018-04-01 · Migraine Disorders
What this study did
NCT02191579 · Allergan
2014-08-05 – 2017-09-01 · Migraine Disorders
What this study did
NCT01516892 · Allergan
2011-12 – 2015-11 · Migraine Disorders
What this study did
NCT02037425 · Cady, Roger, M.D.
2014-04 – 2015-09 · Chronic Migraine
What this study did
NCT02147561 · Allergan
2014-07 – 2015-02 · Migraine Disorders
What this study did
NCT01833130 · Allergan
2013-04 – 2014-09 · Chronic Migraine
What this study did
NCT01071096 · Cady, Roger, M.D.
2010-06 – 2011-06 · Chronic Migraine
What this study did
Other / comorbidity
NCT05806164 · Women and Infants Hospital of Rhode Island
2023-06-06 – 2030-08-01 · Urgency Urinary Incontinence
What this study did
NCT07220382 · The Cleveland Clinic
2025-11-03 – 2029-12-15 · Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
What this study did
NCT07646886 · Peking University
2026-07-01 – 2027-12-01 · Facial Aging, Melomental Folds, Oral Commissure Ptosis
What this study did
NCT06216886 · Stanford University
2024-06-01 – 2027-09-01 · Trigeminal Neuralgia
What this study did
NCT05393921 · University Hospitals Cleveland Medical Center
2026-06-01 – 2027-07 · Benign Prostatic Hyperplasia, Overactive Bladder
What this study did
NCT07295288 · Vanderbilt University Medical Center
2026-07-01 – 2027-06-30 · Synkinesis
What this study did
NCT07794891 · AbbVie
2026-09-09 – 2027-06 · Jawline and Neck Appearance
What this study did
NCT06903975 · Boston Medical Center
2025-05-14 – 2027-03 · Neck Muscle Issue
What this study did
NCT07867379 · Riyadh Elm University
2026-10-11 – 2026-12-24 · Myofascial Pain Syndrome (MPS)
What this study did
NCT07082972 · Istanbul University
2025-09-01 – 2026-12-01 · Myofascial Pain Syndrome (MPS), Masticatory Muscle Pain
What this study did
NCT07387315 · TriHealth Inc.
2026-02 – 2026-12 · Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Bladder Neurogenesis, Urinary Incontinence, Urge, Pelvic Floor Disorders
What this study did
NCT03654066 · Vanderbilt University Medical Center
2019-05-13 – 2026-08-01 · Achalasia
What this study did
NCT05112081 · Nicolai Skov Schiellerup
2022-06-01 – 2026-06-30 · Scrotum Disease, Chronic Pain
What this study did
NCT06734598 · National Taiwan University Hospital
2024-12-01 – 2026-02-01 · Trismus, Head and Neck Cancer, Radiation Therapy Recipient, BOTOX
What this study did
NCT06514430 · Montefiore Medical Center
2025-07 – 2026-02 · Urinary Incontinence, Urinary Incontinence, Urge, Overactive Bladder
What this study did
NCT06695585 · University of Louisville
2024-12-01 – 2025-12-01 · Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
What this study did
NCT04936542 · Ipsen
2021-06-23 – 2025-08-26 · Upper Limb Spasticity
What this study did
NCT06387329 · Walter Reed National Military Medical Center
2024-04-04 – 2025-06-30 · Overactive Bladder, Bladder Pain Syndrome
What this study did
NCT05605756 · Beth Israel Deaconess Medical Center
2023-03-01 – 2024-12-01 · Drug-resistant Focal Seizure
What this study did
NCT06724250 · Mansoura University
2023-08-01 – 2024-09-30 · Obstructed Defaecation Syndrome
What this study did
NCT05519072 · Atlantic Health System
2022-08-16 – 2024-08-16 · Antibiotic Prophylaxis
What this study did
NCT04609020 · Allergan
2023-02-15 – 2024-05-10 · Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality
What this study did
NCT06583343 · Gaziosmanpasa Research and Education Hospital
2022-08-25 – 2024-04-25 · Cerebral Palsy Spastic Diplegia
What this study did
NCT04819360 · Brigitte Schürch
2021-06-01 – 2024-04-21 · Urinary Bladder, Neurogenic, Multiple Sclerosis
What this study did
NCT05308979 · University of California, Irvine
2022-05-01 – 2024-03-31 · Overactive Bladder, Urinary Urge Incontinence, Overactive Bladder Syndrome, Urinary Incontinence, Urge, Urge Incontinence, Urinary Urgency, Urinary Frequency
What this study did
NCT05072821 · National Cheng-Kung University Hospital
2020-10-13 – 2024-03-20 · Scar Keloid
What this study did
NCT05647551 · AbbVie
2023-01-05 – 2023-10-05 · Facial Corrections, Facial Lines
What this study did
NCT05615987 · Konya Beyhekim Training and Research Hospital
2022-12-01 – 2023-10-01 · Spastic Hemiplegia
What this study did
NCT04270526 · Boston Urogynecology Associates
2020-08-15 – 2023-06-30 · Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
What this study did
NCT05719285 · The Cleveland Clinic
2022-12-06 – 2023-06-08 · Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
What this study did
NCT04807920 · Walter Reed National Military Medical Center
2021-09-23 – 2023-06 · Urinary Bladder, Overactive, Pelvic Organ Prolapse
What this study did
NCT05652036 · The Methodist Hospital Research Institute
2022-07-07 – 2023-05-15 · Overactive Bladder
What this study did
NCT04124939 · Wake Forest University Health Sciences
2019-11-10 – 2023-02-23 · Overactive Bladder
What this study did
NCT05006417 · University of Wisconsin, Madison
2022-11-23 – 2022-11-23 · Compartment Syndrome of Leg
What this study did
NCT05157295 · Augusta University
2022-01-01 – 2022-09-30 · Overactive Bladder Syndrome, Overactive Bladder
What this study did
Early phase / not applicable (102)
Migraine
NCT07571889 · Association of Migraine Disorders
2026-03-03 – 2027-01 · Pain From onabotulinumtoxinA Injections
What this study did
NCT07535723 · Beni-Suef University
2026-04 – 2026-12 · Chronic Migraine Headache, OnabotulinumtoxinA, Greater Occipital Nerve Block, Combination Therapy
What this study did
NCT06974617 · Cairo University
2025-05-15 – 2025-10-01 · Sphenopalatine Block, BOTOX, Chronic Migraine
What this study did
NCT05382832 · EPC Education s.r.o.
2022-08-01 – 2025-08-01 · Migraine
What this study did
NCT06122545 · Tanta University
2022-05-01 – 2024-05-01 · Greater Occipital Nerve Block, Medical Treatment, Chronic Migraine
What this study did
NCT00850421 · HealthPartners Institute
2004-04 – 2010-04 · Migraine Headache
What this study did
Other / comorbidity
NCT07180394 · Foundation University Islamabad
2025-09-30 – 2030-08-30 · Strabismic Deviation, Strabismus
What this study did
NCT07930143 · Hospital Clinic of Barcelona
2026-12-07 – 2029-12-06 · Esophagogastric Junction Outflow Obstruction
What this study did
NCT07577310 · University of Alabama at Birmingham
2026-01-22 – 2028-07 · Vocal Tremor
What this study did
NCT07549113 · State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
2024-04-01 – 2028-05-01 · Incisional Hernia Repair, Ventral Hernia Repair
What this study did
NCT06437899 · Hospital LKH Hochsteiermark - Leoben
2023-09-01 – 2027-09 · Overactive Bladder
What this study did
NCT07707791 · Başakşehir Çam & Sakura City Hospital
2026-07-20 – 2027-03-10 · Overactive Bladder (OAB), Botulinum Toxin Injection, Procedural Pain Relief, Anxiety
What this study did
NCT04731961 · University of Virginia
2021-02-23 – 2027-02-28 · Urgency Urinary Incontinence
What this study did
NCT06881147 · IRCCS San Raffaele
2019-04-13 – 2027-01-01 · Cervical Dystonia
What this study did
NCT07665528 · Islamabad Medical and Dental College
2026-06-03 – 2026-12-03 · Anal Fissure Chronic
What this study did
NCT07025642 · Mackay Medical College
2025-07-01 – 2026-12-01 · Overactive Bladder (OAB)
What this study did
NCT07270042 · Latakia University
2025-12-01 – 2026-12-01 · Hyperactive Masseter Muscle
What this study did
NCT07666347 · Tanta University
2026-06-24 – 2026-12-01 · Intraarticular Injection, Botox, Hyaluronic Acid, Knee Osteoarthritis
What this study did
NCT04754737 · Benaroya Research Institute
2021-03-23 – 2026-12 · Antibiotic Stewardship, Overactive Bladder, Onabotulinumtoxin A, UTI
What this study did
NCT07795463 · Pham Ngoc Thach University of Medicine
2026-08-10 – 2026-10-31 · Surgical Wound Healing, Botulinum Toxin, Type A
What this study did
NCT06148961 · Cairo University
2024-02-01 – 2026-10-30 · Excessive Gingival Display
What this study did
NCT07543315 · Tanta University
2023-08-01 – 2026-08-30 · Chronic Anal Fissure
What this study did
NCT07568314 · Islamabad Medical and Dental College
2026-03-02 – 2026-06-01 · Anal Fissure Chronic
What this study did
NCT07673471 · Biruni University
2026-02-09 – 2026-05-08 · Bruxism, Occlusal Changes
What this study did
NCT07057050 · Cairo University
2025-06-30 – 2026-04-01 · Constraint Induced Movement Therapy, Task Oriented Training, Botox Injection, Upper Extremity Function, Stroke
What this study did
NCT07374341 · Pakinam Gheeta
2025-04-10 – 2026-04 · Condylar Fractures, Subcondylar Fracture
What this study did
NCT07545200 · Kahramanmaras Sutcu Imam University
2025-09-30 – 2026-02-15 · Bruxism, Myofascial Pain, Masseter Muscle Hypertrophy
What this study did
NCT05191719 · Rebecka Ohm
2022-02-01 – 2026-02 · Facial Paralysis, Facial Palsy, Peripheral Facial Palsy, Peripheral Facial Paralysis, Bell Palsy, Synkinesis
What this study did
NCT05910983 · Menoufia University
2025-01-01 – 2025-12-01 · BPH, Intravesical Botox, Bipolar Enucleation of the Prostate, Overactive Bladder, Bladder Outlet Obstruction
What this study did
NCT06952218 · Cairo University
2025-12-01 – 2025-12-01 · Gummy Smile Due to Hypermobile Upper Lip
What this study did
NCT02315950 · Cedars-Sinai Medical Center
2014-12 – 2025-12 · Overactive Bladder
What this study did
NCT06207955 · Fayoum University
2024-01-18 – 2025-09-11 · TMJ Disc Disorder, TMJ Pain
What this study did
NCT06577285 · Cairo University
2024-06-01 – 2025-06-01 · Excessive Gingival Display
What this study did
NCT04994990 · Northwell Health
2023-05-25 – 2025-05-30 · Rhytides
What this study did
NCT07331844 · Fatih Sultan Mehmet Training and Research Hospital
2024-05-15 – 2025-05-15 · Stroke, Spastic Hemiplegia
What this study did
NCT07385742 · Suez Canal University
2024-01-10 – 2025-04-19 · Temporomandibular Joint Internal Derangement, Temporomandibular Joint Disorders, Temporomandibular Disorders (TMD), TMJ Pain
What this study did
NCT06840730 · Hacettepe University
2024-06-03 – 2025-04-13 · Myofascial Pain - Dysfunction Syndrome of TMJ
What this study did
NCT06674733 · Bezmialem Vakif University
2024-10-11 – 2025-03-28 · Bruxism, Sleep
What this study did
NCT06553950 · Cairo University
2024-08-14 – 2025-02-01 · Mandibular Splint, Botox, Lateral Pterygoid, Cervical Muscle Activity, Temporomandibular Disorders
What this study did
NCT07076355 · Tanta University
2024-05-23 – 2024-12-26 · Anterior Disc Displacement
What this study did
NCT04240080 · Mayo Clinic
2020-01-10 – 2024-12 · Wrinkle
What this study did
NCT04938102 · University of Kansas Medical Center
2022-07 – 2024-10-11 · Esophagogastric Junction Disorder
What this study did
NCT05894109 · University of New Mexico
2024-08 – 2024-10 · Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin, Zinc Supplementation for Botulinum Toxin Treatment of the Forehead, Glabellar Frown Lines, Botulinum Toxin, Cosmetic, Adjuvant Oral Zinc and Botulinum Toxin
What this study did
NCT06319898 · Wake Forest University Health Sciences
2024-05-22 – 2024-08-12 · Anxiety, Pain, Burnout, Professional
What this study did
NCT04383912 · Nova Scotia Health Authority
2020-11-18 – 2024-07 · Direct Brow Lift, Scarring
What this study did
NCT06282679 · Nanjing First Hospital, Nanjing Medical University
2022-04-01 – 2024-06-28 · Rosacea, Botulinum Toxin
What this study did
NCT06059066 · The Methodist Hospital Research Institute
2023-10-04 – 2024-04-30 · Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
What this study did
NCT04448171 · Mayo Clinic
2020-10-28 – 2023-12-31 · Overactive Bladder
What this study did
Used as active comparator (63)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (30)
Migraine
NCT05598723 · Naval Medical Center Camp Lejeune
2023-02-24 – 2027-08-24 · Chronic Migraine
What this study did
Other / comorbidity
NCT06937944 · JHM BioPharma (Tonghua) Co. , Ltd.
2025-04-30 – 2026-09 · Moderate to Severe Glabellar Lines
What this study did
NCT07013279 · Daewoong Pharmaceutical Co. LTD.
2025-07-15 – 2026-03-31 · Glabellar Lines
What this study did
NCT06585696 · Cutia Therapeutics(Wuxi)Co.,Ltd
2024-06-24 – 2025-11-20 · Glabellar Frown Lines
What this study did
NCT05801146 · Hugel
2024-01-04 – 2025-10 · Glabellar Lines
What this study did
NCT06499688 · Chongqing Claruvis Pharmaceutical Co., Ltd.
2023-12-28 – 2024-05-31 · Moderate to Severe Glabellar Lines
What this study did
NCT05804656 · CKD Bio Corporation
2023-04-13 – 2023-11-20 · Glabellar Lines
What this study did
NCT05364580 · Protox Inc.
2023-03-06 – 2023-10-06 · Glabellar Frown Lines
What this study did
NCT05463965 · Galderma R&D
2022-07-29 – 2023-06-15 · Moderate to Severe Glabellar Lines
What this study did
NCT06840158 · Innopharm LLC
2021-10-15 – 2022-06-29 · Cerebral Palsy (CP)
What this study did
NCT05059587 · Medytox Korea
2021-08-30 – 2022-03-29 · Glabellar Frown Lines
What this study did
NCT07622004 · INIBIO Co., Ltd.
2021-05-27 – 2022-03-05 · Glabellar Lines
What this study did
NCT04830345 · EuBiologics Co.,Ltd
2020-06-29 – 2021-10-01 · Glabellar Frown Lines
What this study did
NCT05531968 · BMI Korea
2021-02-09 – 2021-09-17 · Glabellar Lines
What this study did
NCT03758235 · University Of Perugia
2018-09-01 – 2021-09-01 · Overactive Bladder Syndrome
What this study did
NCT06354127 · Daewoong Pharmaceutical Co. LTD.
2020-08-12 – 2021-01-25 · Moderate to Severe Glabellar Lines
What this study did
NCT04081402 · Huons Co., Ltd.
2018-11-01 – 2020-02 · Crow's Feet Lines
What this study did
NCT03837561 · Medy-Tox
2018-12-13 – 2019-06-03 · Glabellar Frown Lines
What this study did
NCT03440671 · Huons Co., Ltd.
2017-11-30 – 2018-12-30 · Glabellar Frown Lines
What this study did
NCT03289702 · Medy-Tox
2017-11-13 – 2018-11-09 · Muscle Spasticity
What this study did
NCT05380154 · Hugel
2017-05-09 – 2018-07-06 · Glabellar Lines
What this study did
NCT03216473 · Medy-Tox
2016-05-25 – 2017-07-04 · Essential Blepharospasm
What this study did
NCT03216408 · Medy-Tox
2016-03-30 – 2017-03-07 · Glabellar Lines
What this study did
NCT03905304 · Medy-Tox
2013-01-09 – 2014-08-05 · Cervical Dystonia
What this study did
NCT01787344 · Hugel
2012-03 – 2014-08 · Other Infantile Cerebral Palsy
What this study did
NCT01915459 · Hugel
2013-06 – 2014-07 · Stroke, Spasticity
What this study did
NCT01629875 · Daewoong Pharmaceutical Co. LTD.
2012-03 – 2012-11 · Moderate to Severe Glabellar Line
What this study did
NCT01180348 · Azidus Brasil
2011-08 – 2012-09 · Wrinkles
What this study did
NCT01237977 · Medy-Tox
2009-11-23 – 2010-09-30 · Skin Aging
What this study did
NCT00777803 · Merz Pharmaceuticals GmbH
2008-11 – 2009-05 · Glabellar Frown Lines
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT06783114 · Chongqing Claruvis Pharmaceutical Co., Ltd.
2024-09-14 – 2026-09-30 · Upper Limb Spasticity
What this study did
NCT06676475 · Misr University for Science and Technology
2024-12-01 – 2025-08 · Myofacial Pain, Trigger Points, Myofascial
What this study did
NCT01910363 · University of Tokushima
2013-07 – 2014-01 · Lower Limb Spasticity After Stroke
What this study did
Phase 2 (5)
Other / comorbidity
NCT06034288 · Walter Reed National Military Medical Center
2023-05-04 – 2024-09-30 · Overactive Bladder Syndrome
What this study did
NCT05320393 · Evolus, Inc.
2022-03-30 – 2023-05-22 · Glabellar Frown Lines
What this study did
NCT02188277 · Merz Pharmaceuticals GmbH
2014-07 – 2016-12 · Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation
What this study did
NCT01588574 · Medy-Tox
2012-08 – 2013-12 · Cervical Dystonia
What this study did
Phase 1/2 (5)
Other / comorbidity
NCT05743634 · Chongqing Claruvis Pharmaceutical Co., Ltd.
2022-03-22 – 2023-02-13 · Moderate to Severe Glabellar Lines
What this study did
NCT04996810 · Protox Inc.
2020-12-10 – 2021-05-26 · Glabellar Frown Lines
What this study did
NCT03970876 · EuBiologics Co.,Ltd
2019-04-19 – 2019-12-23 · Moderate to Severe Glabellar Lines
What this study did
NCT02961673 · Huons Co., Ltd.
2016-09 – 2017-03 · Glabellar Lines
What this study did
Phase 1 (13)
Other / comorbidity
NCT07292025 · Jetema Co., Ltd.
2023-06-29 – 2024-09-04 · Upper Limb Spasticity Post-Stroke
What this study did
NCT05956509 · AbbVie
2024-01-12 – 2024-06-02 · Upper Limb Spasticity
What this study did
NCT06212960 · Daewoong Pharmaceutical Co. LTD.
2023-11-28 – 2024-03-21 · Glabellar Lines
What this study did
NCT05807412 · Lupo Center for Aesthetic and General Dermatology
2023-05-01 – 2024-02-26 · Rhytides
What this study did
NCT05382767 · CKD Bio Corporation
2022-06-02 – 2022-12-08 · Post-stroke Upper Limb Spasticity
What this study did
NCT05428930 · CKD Bio Corporation
2022-06-22 – 2022-10-25 · Glabellar Lines
What this study did
NCT05292638 · CKD Bio Corporation
2022-02-15 – 2022-06-10 · Glabellar Lines
What this study did
NCT04944953 · Hugel
2021-06-11 – 2021-12-16 · Glabellar Lines
What this study did
NCT04171258 · Hugel
2020-05-26 – 2021-10-26 · Cervical Dystonia
What this study did
NCT04186442 · Hugel
2020-05-12 – 2021-10-26 · Overactive Bladder
What this study did
NCT03371342 · Medy-Tox
2017-12-13 – 2018-09-05 · Overactive Bladder
What this study did
NCT05164003 · Medy-Tox
2017-07-17 – 2017-09-29 · Muscle Spasticity
What this study did
NCT03796351 · Medy-Tox
2012-09 – 2013-01 · Healthy Volunteers
What this study did
Phase 4 (4)
Other / comorbidity
NCT05968885 · Mackay Memorial Hospital
2021-10-01 – 2026-12-31 · Urinary Bladder, Overactive, Urodynamics, Effect of Drug
What this study did
NCT06796855 · Bagcilar Training and Research Hospital
2023-02-01 – 2024-02-01 · Overactive Bladder Syndrome, Refractory Overactive Bladder
What this study did
NCT05277337 · Galderma R&D
2022-02-04 – 2022-10-12 · Glabellar Frown Lines
What this study did
NCT02096081 · Merz North America, Inc.
2014-02 – 2014-11 · Glabellar Frown Lines
What this study did
Early phase / not applicable (3)
Migraine
NCT06684249 · Zagazig University
2024-11-10 – 2025-07-10 · Chronic Migraine, Chronic Migraine, Headache
What this study did
Other / comorbidity
NCT06633445 · Mahmoud Akram Khodir
2023-11-01 – 2024-09-01 · Anterior Disc Displacement
What this study did
NCT02325063 · Centre Hospitalier Universitaire de Nīmes
2015-12-17 – 2017-05-02 · Epicondylitis, Lateral Humeral, Tennis Elbow
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (3)
Migraine
NCT01700387 · Cady, Roger, M.D.
2012-10 – 2014-08 · Chronic Migraine
What this study did
Other / comorbidity
NCT02297100 · Wake Forest University Health Sciences
2014-12 – 2018-01-10 · Interstitial Cystitis
What this study did
NCT02600715 · Edgar LeClaire, MD
2015-11 – 2017-06-26 · Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
What this study did
Early phase / not applicable (2)
Migraine
NCT02953015 · Universita di Verona
2016-01 – 2017-12 · Headache
What this study did
Other / comorbidity
NCT06075134 · Cairo University
2024-11-01 – 2026-08 · Excessive Gingival Display
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Migraine: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
onabotulinumtoxinA (Botox): this drugApprovedBiologic (subtype unspecified)acetylcholine release, Acetylcholine Release Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Aspirin / Acetaminophen / Caffeine (Excedrin Migraine)Approved—Nonsteroidal Anti-inflammatory Drug, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Atogepant (Qulipta)ApprovedSmall moleculeCGRP receptorReliable signal
NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206)
NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33)
Celecoxib (Elyxyb)ApprovedSmall moleculeCOX-2Partial signalNo reviewed efficacy summary in this indication
Diclofenac Potassium (Cambia)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine (Atzumi)ApprovedSmall molecule5-HT1D receptorPartial signal
NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed
NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed
Dihydroergotamine Mesylate (Brekiya)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (D.H.E. 45)
ApprovedUS marketing discontinued
Small molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (Migranal)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eletriptan (Relpax)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Eptinezumab (Vyepti)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9)
NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7)
Erenumab (Aimovig)ApprovedMonoclonal antibodyCGRP receptorReliable signal
NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45)
NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18)
Ergotamine / Caffeine (Cafergot)
ApprovedUS marketing discontinued
Small moleculeAlpha-adrenergic receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Fremanezumab (Ajovy)ApprovedMonoclonal antibodyCGRP ligandPartial signal
NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results).
NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results).
Frovatriptan (Frova)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Galcanezumab (Emgality)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001.
NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001.
Ibuprofen (Advil Migraine)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Meloxicam / Rizatriptan (Symbravo)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugReliable signalFeatured results are safety only in this race
Naratriptan (Amerge)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Rimegepant (Nurtec ODT)ApprovedSmall moleculeCGRP receptorReliable signal
NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14)
NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91)
Rizatriptan (Maxalt)ApprovedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy only in this race
Rizatriptan (RizaFilm)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Onzetra Xsail)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Tosymra)ApprovedSmall molecule5-HT1B/1D receptorWeak signalFeatured results are safety only in this race
Sumatriptan Succinate (Sumavel DosePro)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zembrace SymTouch)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Injection (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Nasal Spray (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Tablets (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan / Naproxen Sodium (Treximet)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugWeak signalNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001).
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Ubrogepant (Ubrelvy)ApprovedSmall moleculeCGRP receptorReliable signal
NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants
Zavegepant (Zavzpret)ApprovedSmall moleculeCGRP receptorReliable signalNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig Nasal Spray)ApprovedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication
Almotriptan (Axert)US approval withdrawnSmall molecule5-HT1B/1D receptorWeak signalNo reviewed efficacy summary in this indication
ElismetrepPhase 3—TRPM8not yet gradedNo reviewed efficacy summary in this indication
IncobotulinumtoxinA (Xeomin)Phase 3Protein / enzyme therapeuticacetylcholine releasenot yet gradedNo reviewed efficacy summary in this indication
Rizatriptan / NaproxenPhase 3Small molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Naltrexone / Acetaminophen (ALLOD-2)Phase 2/3—Opioid receptornot yet gradedNo reviewed efficacy summary in this indication
BHV-2100Phase 2—TRPM3not yet gradedNo reviewed efficacy summary in this indication
EVO756Phase 2Small moleculeMRGPRX2not yet gradedNo reviewed efficacy summary in this indication
ABBV-2002
—(overall)
UndisclosedPAR-2not yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv)
—(overall)
—5-HT1D receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina)
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Lasmiditan (Reyvow)DiscontinuedSmall molecule5-HT1F receptorReliable signalNo reviewed efficacy summary in this indication
Propranolol (Inderal)DiscontinuedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zecuity)DiscontinuedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy and safety only in this race
Sumatriptan Succinate Auto-Injector (Alsuma)DiscontinuedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig)DiscontinuedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(31 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Botox (onabotulinumtoxinA) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 4Overactive Bladder, Neurogenic Bladder, Urge Incontinence, Pain, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Bladder …Not yet recruiting
Est. primary completion 2026-11 · NCT07387315 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Wrinkles and RhytidesNot yet recruiting
Est. primary completion 2026-12 · NCT07923448 · CT.gov ↗
What to watch
Early phase / not applicableIntraarticular Injection, Botox, Hyaluronic Acid, Knee OsteoarthritisRecruiting
Est. primary completion 2026-12-01 · NCT07666347 · CT.gov ↗
What to watch
Phase 4Myofascial Pain Syndrome (MPS)Not yet recruiting
Est. primary completion 2026-12-24 · NCT07867379 · CT.gov ↗
What to watch
2027 (17)
January 2027 (1)
Early phase / not applicableMigraineRecruiting
Est. primary completion 2027-01 · NCT07571889 · CT.gov ↗
What to watch
February 2027 (5)
Phase 1Glabellar LinesActive not recruiting
Est. primary completion 2027-02 · NCT07756580 · CT.gov ↗
What to watch
Phase 2Cleft Lip, Cleft Lip ScarRecruiting
Est. primary completion 2027-02 · NCT07880860 · CT.gov ↗
What to watch
Phase 4Trigeminal NeuralgiaRecruiting
Est. primary completion 2027-02-01 · NCT06216886 · CT.gov ↗
What to watch
Early phase / not applicableOveractive Bladder (OAB), Botulinum Toxin Injection, Procedural Pain Relief, AnxietyNot yet recruiting
Est. primary completion 2027-02-20 · NCT07707791 · CT.gov ↗
What to watch
Early phase / not applicableUrgency Urinary IncontinenceActive not recruiting
Est. primary completion 2027-02-28 · NCT04731961 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Neck Muscle IssueRecruiting
Est. primary completion 2027-03 · NCT06903975 · CT.gov ↗
What to watch
Phase 1Pelvic Floor DisordersRecruiting
Est. primary completion 2027-03-22 · NCT06796985 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2/3Base-of-thumb Osteoarthritis, OsteoarthritisRecruiting
Est. primary completion 2027-05 · NCT06902805 · CT.gov ↗
What to watch
Early phase / not applicableIncisional Hernia Repair, Ventral Hernia RepairRecruiting
Est. primary completion 2027-05-01 · NCT07549113 · CT.gov ↗
What to watch
June 2027 (2)
Phase 4Jawline and Neck AppearanceRecruiting
Est. primary completion 2027-06 · NCT07794891 · CT.gov ↗
What to watch
Phase 4Facial Aging, Melomental Folds, Oral Commissure PtosisNot yet recruiting
Est. primary completion 2027-06-01 · NCT07646886 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3Transfer Dysphagia, Oropharyngeal Dysphagia, Cricopharyngeus Muscle DysfunctionRecruiting
Est. primary completion 2027-08-31 · NCT04695600 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4MigraineNot yet recruiting
Est. primary completion 2027-10 · NCT07837570 · CT.gov ↗
What to watch
December 2027 (3)
Phase 1WrinklesActive not recruiting
Est. primary completion 2027-12 · NCT02019004 · CT.gov ↗
What to watch
Phase 4Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia …Recruiting
Est. primary completion 2027-12-15 · NCT07220382 · CT.gov ↗
What to watch
Phase 2/3Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia …Recruiting
Est. primary completion 2027-12-31 · NCT06721520 · CT.gov ↗
What to watch
2028 (5)
February 2028 (1)
Phase 3Buerger Disease, Raynaud SyndromeNot yet recruiting
Est. primary completion 2028-02 · NCT05698979 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Overactive BladderRecruiting
Est. primary completion 2028-03-31 · NCT07648290 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Spinal Cord InjuriesEnrolling by invitation
Est. primary completion 2028-04-30 · NCT06793683 · CT.gov ↗
What to watch
July 2028 (1)
Early phase / not applicableVocal TremorRecruiting
Est. primary completion 2028-07 · NCT07577310 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Prostate CancerNot yet recruiting
Est. primary completion 2028-11-01 · NCT07796490 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 3MigraineRecruiting
Est. primary completion 2029-01-31 · NCT07040813 · CT.gov ↗
What to watch
March 2029 (1)
Early phase / not applicableEsophagogastric Junction Outflow ObstructionNot yet recruiting
Est. primary completion 2029-03-06 · NCT07930143 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Masticatory Myofascial Pain SyndromeNot yet recruiting
Est. primary completion 2029-10 · NCT07878780 · CT.gov ↗
What to watch
2030 (2)
August 2030 (1)
Early phase / not applicableStrabismic Deviation, StrabismusNot yet recruiting
Est. primary completion 2030-08-30 · NCT07180394 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Fecal IncontinenceRecruiting
Est. primary completion 2030-09 · NCT06785844 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 October 2025Topline resultPhase 2 ELATE of onabotulinumtoxinA in essential tremor met its primary endpoint
AbbVie · Source ↗